Bronstein, Gewirtz & Grossman LLC announces that Amylyx Pharmaceuticals, Inc. Investors who have suffered significant losses have the opportunity to lead a class action lawsuit!

Bronstein, Gewirtz & Grossman LLC announces that Amylyx Pharmaceuticals, Inc.  Investors who have suffered significant losses have the opportunity to lead a class action lawsuit!

New York, February 12, 2024 /PRNewswire/ — Lawyer Announcement — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain of its officers.

Category definition:

This lawsuit seeks to recover damages for the defendants The alleged one Violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Amylyx securities between November 11, 2022 And November 8, 2023, inclusive (“Class Period”). These investors are encouraged to join this cause by visiting the company’s website: bgandg.com/AMLX.

Case details:

Amylyx is a commercial-stage biotechnology company involved in the discovery and development of treatments for amyotrophic lateral sclerosis (“ALS”), also known as Lou Gehrig Diseases and other neurological diseases. The Company’s products include, among others, AMX0035 (commercially referred to as “RELYVRIO” in the United States), a dual UPR-Bax apoptosis inhibitor consisting of sodium phenylbutyrate and taurorsodiol, for the treatment of amyotrophic lateral sclerosis in adults in the United States.

Following the instructions of the US Food and Drug Administration September 2022 In approving RELYVRIO to treat amyotrophic lateral sclerosis in adults in the United States, the defendants continually promoted the drug’s commercial prospects and prescription rate.

Complaint Allegedly That, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and future prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Defendants overstated RELYVRIO’s business prospects; (2) patients discontinued treatment with RELYVRIO after six months; (3) the rate at which new patients started treatment with RELYVRIO was decreasing; (4) Accordingly, Defendants also overstated RELYVRIO’s prescription rate; (5) Defendants attempted to hide past negative trends from investors and the market by preventing analysts from viewing RELYVRIO’s prescription data; and (6) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

What then?

A class action lawsuit has already been filed. If you would like to review a copy of the complaint, you can visit the company’s website: bgandg.com/AMLX or you can call Peretz Bronstein, Esq. Or the legal clerk and customer relations manager, Yael Nathanson From Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffer a loss on Amylyx you even have April 9, 2024To request that the court appoint you as lead plaintiff. Your ability to participate in any recovery does not require that you serve as lead plaintiff.

There is no cost to you

We represent investors in class actions on a contingency fee basis. This means that we will ask the court to reimburse us for out-of-pocket expenses and attorney fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Goertz and Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents securities investors scam Class Actions and Shareholder Derivative Actions. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Lawyer advertisement. Previous results do not guarantee similar results.

communication:
Bronstein, Goertz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
332-239-2660 | (email protected)

SOURCE Bronstein, Goertz & Grossman, LLC

    (Tags for translation)Bronstein

You may also like...

Leave a Reply